| 本文已被：浏览 423次 下载 68次 |
码上扫一扫！ |
|
|
| 宣肺败毒方中药单体通过IL-6/IL-6R调控的抗炎作用筛选研究 |
|
常惠琳1, 罗子娟1, 李舒宁1, 高盼微1, 王萌1, 袁庆1,2,3, 苗琳1,2,3, 张晗1,2,3, 柴丽娟1,2,3
|
|
1.天津中医药大学中医药研究院, 天津 301617;2.天津中医药大学组分中药国家重点实验室, 天津 301617;3.方剂学教育部重点实验室, 天津 301617
|
|
| 摘要: |
| [目的] 基于分子对接及体外竞争酶联免疫吸附测定（ELISA）实验，筛选宣肺败毒方（XFBD）中具有抗炎活性的中药单体成分。[方法] 采用Discovery Studio2.5，对XFBD所含的963种中药单体成分与白细胞介素-6（IL- 6）受体（IL-6R）进行分子对接；通过竞争性ELISA法构建IL-6/IL-6R拮抗剂筛选模型，验证单体成分对IL-6/IL-6R结合的抑制作用。[结果] 分子对接结果显示，XFBD中19种中药单体成分与IL-6R有良好的结合潜力。竞争性ELISA实验结果显示，IL-6R与IL-6最佳结合浓度为2 μg/mL，在此条件构建IL-6/IL-6R拮抗剂筛选模型。在此模型基础上，对19种中药单体进行抑制活性验证。结果显示这19种中药单体均能显著抑制IL-6与IL-6R的结合。其中，橙皮苷、苦杏仁苷、异鼠李素-3-O-芸香糖苷、牡荆素、马钱苷、硬脂酸、山柰酚、对甲氧基肉桂酸等8种中药单体抑制率达50 %以上。[结论] 宣肺败毒方中多种单体成分可通过阻断IL-6/IL-6R结合发挥抗炎作用，这为其抗炎活性提供了物质基础。 |
| 关键词: 宣肺败毒方 白细胞介素-6/白细胞介素-6受体拮抗剂 中药单体 分子对接 竞争性酶联免疫吸附测定 抗炎 |
| DOI：10.11656/j.issn.1672-1519.2026.02.10 |
| 分类号:R285.5 |
| 基金项目:天津市科技计划项目（22ZXGBSY00020）；现代中药新质生产力科技创新工程专项（24ZXZKSY00010） |
|
| Screening of anti-inflammatory monomeric compounds from Xuanfei Baidu Decoction via regulation of the IL-6/IL-6R pathway |
|
CHANG Huilin1, LUO Zijuan1, LI Shuning1, GAO Panwei1, WANG Meng1, YUAN Qing1,2,3, MIAO Lin1,2,3, ZHANG Han1,2,3, CHAI Lijuan1,2,3
|
|
1.Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China;2.State Key Laboratory of Component Chinese Medicines, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China;3.Key Laboratory of Pharmacology of Traditional Chinese Medical Formulae, Ministry of Education, Tianjin 301617, China
|
| Abstract: |
| [Objective]To screen the Chinese herbal monomer components from Xuanfei Baidu Formula(XFBD)with anti-inflammatory activity based on molecular docking and competitive enzyme - linked immunosorbent assay (ELISA) experiments.[Methods]Using Discovery Studio 2.5, molecular docking was performed between 963 herbal monomer components contained in XFBD and interleukin-6 receptor(IL-6R). A competitive ELISA-based screening model for IL-6/IL-6R antagonists was established to validate the inhibitory effects of monomer components on IL-6/IL-6R binding.[Results]Molecular docking results indicated that 19 monomer components from XFBD exhibited strong binding potential to IL - 6R. Competitive ELISA results showed that the optimal binding concentration between IL-6R and IL-6 was 2 μg/mL, under which the IL-6/IL-6R antagonist screening model was constructed. Using this model, the inhibitory activity of the 19 monomer components was verified. The results demonstrated that all 19 components significantly inhibited the binding of IL-6 to IL-6R. Among them, eight components-hesperidin, amygdalin, isorhamnetin-3-O-rutinoside, vitexin, loganin, stearic acid, kaempferol, and p-methoxycinnamic acid-showed inhibition rates exceeding 50%.[Conclusion]Multiple monomer components in Xuanfei Baidu Formula exert anti-inflammatory effects by blocking IL- 6/IL-6R binding, providing a material basis for its anti- inflammatory activity. |
| Key words: Xuanfei Baidu Decoction IL-6/IL-6R antagonist Chinese medicine monomers molecular docking competitive enzyme-linked immunosorbent assay anti-inflammatory |
